News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
ThromboGenics Ltd. to Absorb Subsidiary Thromb-X, NV
May 23, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BRUSSELS (Thomson Financial) - Belgian biotechnology company ThromboGenics NV said it plans to absorb its subsidiary Thromb-X. The company said the transaction will issue no new shares or cash payment.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
Collaboration
Novartis Sticks With Monte Rosa in Second Molecular Glue Deal Worth up to $5.7B
September 15, 2025
·
2 min read
·
Tristan Manalac
Europe
AstraZeneca Suspends $270M UK Commitment Months After Scrapping Vaccine Facility
September 15, 2025
·
2 min read
·
Tristan Manalac
IPO
UPDATE: Neuroscience Biotech LB Pulls Off Upsized $285M IPO
September 11, 2025
·
2 min read
·
Annalee Armstrong
Podcast
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
September 10, 2025
·
1 min read
·
Jef Akst
